Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial

DOI Web Site Web Site 14 Citations
  • Craig Campbell
    Pediatrics, Epidemiology and Clinical Neurological Sciences Western University London Ontario Canada
  • Hugh J. McMillan
    Children's Hospital of Eastern Ontario University of Ottawa Ottawa Ontario Canada
  • Jean K. Mah
    Alberta Children's Hospital University of Calgary Calgary Alberta Canada
  • Mark Tarnopolsky
    McMaster University Medical Centre Hamilton Ontario Canada
  • Kathryn Selby
    British Columbia Children's Hospital University of British Columbia Vancouver British Columbia Canada
  • Ty McClure
    Acceleron Pharma Cambridge Massachusetts USA
  • Dawn M. Wilson
    Acceleron Pharma Cambridge Massachusetts USA
  • Matthew L. Sherman
    Acceleron Pharma Cambridge Massachusetts USA
  • Diana Escolar
    Kennedy Krieger Institute Johns Hopkins Medical School Baltimore Maryland USA
  • Kenneth M. Attie
    Acceleron Pharma Cambridge Massachusetts USA

Description

<jats:title>ABSTRACT</jats:title><jats:p><jats:italic>Introduction</jats:italic>: ACE‐031 is a fusion protein of activin receptor type IIB and IgG1‐Fc, which binds myostatin and related ligands. It aims to disrupt the inhibitory effect on muscle development and provide potential therapy for myopathies like Duchenne muscular dystrophy (DMD). <jats:italic>Methods</jats:italic>: ACE‐031 was administered subcutaneously every 2–4 weeks to DMD boys in a randomized, double‐blind, placebo‐controlled, ascending‐dose trial. The primary objective was safety evaluation. Secondary objectives included characterization of pharmacokinetics and pharmacodynamics. <jats:italic>Results</jats:italic>: ACE‐031 was not associated with serious or severe adverse events. The study was stopped after the second dosing regimen due to potential safety concerns of epistaxis and telangiectasias. A trend for maintenance of the 6‐minute walk test (6MWT) distance in the ACE‐031 groups compared with a decline in the placebo group (not statistically significant) was noted, as was a trend for increased lean body mass and bone mineral density (BMD) and reduced fat mass. <jats:italic>Conclusion</jats:italic>: ACE‐031 use demonstrated trends for pharmacodynamic effects on lean mass, fat mass, BMD, and 6MWT. Non–muscle‐related adverse events contributed to the decision to discontinue the study. Myostatin inhibition is a promising therapeutic approach for DMD. <jats:italic>Muscle Nerve</jats:italic> <jats:bold>55</jats:bold>: 458–464, 2017</jats:p>

Journal

Citations (14)*help

See more

Report a problem

Back to top